Dutch researchers report that in patients with Type 1 diabetes, continuous intraperitoneal insulin infusion (CIPII) using an implantable pump achieves a higher degree of euglycemia than do multiple daily insulin injections.
Advertisement
Lead investigator Dr. Susan J. Logtenberg stated that, "With CIPII, compared to intensive subcutaneous insulin regimens, it is possible to reach better glycemic control in terms of A1c, and subjects spend more time in euglycemia without the occurrence of more hypoglycemic events."
Dr. Logtenberg of Isala Clinics, Zwolle, and colleagues, came to this conclusion after an open-label, 16-month, randomized crossover study in 24 patients.
With CIPII, the weekly incidence of grade 1 hypoglycemic events was 3.5, compared to 4.0 with subcutaneous injection. The absolute mean A1c was 0.76% lower with CIPII.
Baseline time spent in euglycemia was 45.2%. This proportion increased with CIPII, and with injection it fell. After adjustment, the difference amounted to 10.9%.
The researchers point out that the approach is expensive but, "We recommend consideration of CIPII as a treatment option for those patients with Type 1 diabetes who fail to achieve satisfactory glycemic control with other intensive insulin treatment regimens."
Given the encouraging findings, Dr. Logtenberg added that, "In the near future we hope to report about the effects on quality of life, as well."
DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.
Copyright @ 1999-2012 Diabetes In Control, Inc.. All rights reserved.